[{"id":"ae36f3a0-eb85-44ba-afee-09efb5463d1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01434316","created_at":"2021-01-18T05:55:48.375Z","updated_at":"2025-02-25T16:51:08.574Z","phase":"Phase 1","brief_title":"Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01434316","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • RAD51","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • dinaciclib (MK-7965)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/11/2011","start_date":" 11/11/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-04"},{"id":"efa29a1e-2944-49b3-b0e3-5e8f2332ce4a","acronym":"NCI-2018-01053","url":"https://clinicaltrials.gov/study/NCT01676753","created_at":"2021-01-18T07:15:38.079Z","updated_at":"2025-02-25T16:02:39.035Z","phase":"Phase 1b","brief_title":"Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer","source_id_and_acronym":"NCT01676753 - NCI-2018-01053","lead_sponsor":"Jo Chien","biomarkers":" PGR","pipe":" | ","alterations":" PGR expression","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • dinaciclib (MK-7965)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 12/28/2016","start_date":" 12/28/2016","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2022-09-21"},{"id":"07bce700-fe42-4bb9-aa13-93f6cdc1621a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01624441","created_at":"2021-01-18T06:58:11.122Z","updated_at":"2024-07-02T16:37:12.599Z","phase":"Phase 1","brief_title":"Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01624441","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • MCL1","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • ER • PGR • MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epirubicin • dinaciclib (MK-7965)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/21/2012","start_date":" 08/21/2012","primary_txt":" Primary completion: 09/10/2013","primary_completion_date":" 09/10/2013","study_txt":" Completion: 09/10/2013","study_completion_date":" 09/10/2013","last_update_posted":"2018-03-30"}]